Clinical trials: Cyclooxygenase 2 Inhibitors
Rupture; Graafian Follicle
Study of a COX-2 Inhibitor for Prevention of Ovulation
In this study the investigators propose to evaluate a COX-2 inhibitor(meloxicam) to assess its effect on follicular development and find out if this regimen delays or blocks ovulation while maintaining ovarian cyclicity.
- Trial name
- NCT01346137
- Testing
- Meloxicam
- Where
- Chile
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Instituto Chileno de Medicina Reproductiva
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
SERRAC is a prospective, multicentre, randomized phase II trial. 138 LARC (T3-4/N+M0, distance from anal verge ≤10cm) patients will be treated with neoadjuvant therapy and assigned to Group A and Group B (1:1).
- Trial name
- NCT07150949
- Testing
- Long-course radiotherapy, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Fudan University
Hallux Valgus, Postoperative Pain
A Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain
The investigators hypothesize that cyclooxygenas-II-selective inhibitors (Coxibs) provide a better patients assessed overall satisfaction when used for pain management after elective hallux valgus surgery as compared to…
- Trial name
- NCT01190722
- Testing
- etoricoxib, Diclofenac
- Sponsor
- Karolinska Institutet
Non-Small Cell Lung Cancer
Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
The primary purpose of the study is to investigate if daily treatment with celecoxib, an inhibitor of cyclooxygenase-2, can prolong survival in patients with advanced non-small cell lung cancer who receive anticancer chemotherapy…
- Trial name
- CYCLUS (NCT00300729)
- Testing
- Celecoxib
- Where
- 13 sites in Sweden
- Volunteers
- 319 people
- Sponsor
- University Hospital, Linkoeping
Pancreatitis, Acute
COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a…
- Trial name
- NCT02964403
- Testing
- Cox-2, Indomethacin
- Volunteers
- 2,700 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University